Korsana Biosciences/$KRSA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Korsana Biosciences
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
- Ticker
- $KRSA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 19
- Headquarters
- Waltham, United States
- Website
- korsana.com
KRSA Metrics
BasicAdvanced
$1.5B
-
-$13.37
1.73
-
Price and volume
Market cap
$1.5B
Beta
1.73
52-week high
$37.27
52-week low
$21.00
Average daily volume
148K
Financial strength
Current ratio
17.398
Quick ratio
17.276
Long term debt to equity
0.007
Total debt to equity
0.009
Profitability
Management effectiveness
Valuation
Price to book
-4.06
Price to tangible book (TTM)
-4.06
Price to free cash flow (TTM)
-2.782
Free cash flow yield (TTM)
-35.94%
Free cash flow per share (TTM)
-11.444
Growth
What the Analysts think about KRSA
Analyst ratings (Buy, Hold, Sell) for Korsana Biosciences stock.
Analyst projections of the future price of Korsana Biosciences stock.
Bulls say / Bears say
Korsana had $456.2 million in cash at the end of September and expects it to fund operations into 2029. That gives it room to advance KRSA-028 through planned clinical milestones without an immediate need to raise more capital. (Korsana Biosciences)
Company-reported preclinical tests in non-human primates found KRSA-028 had a longer half-life than Roche’s trontinemab and did not deplete reticulocytes. If these early results translate to people, they could support a differentiated safety and dosing profile. (SEC)
Approved amyloid-targeting drugs provide some validation for the treatment approach, and analysts cited about $1.4 billion in annualised global sales for the class. Wedbush also pointed to existing regulatory and reimbursement pathways, which could help if KRSA-028 proves effective and safer or easier to use. (Investing.com)
KRSA-028 has not yet produced human data: healthy-volunteer results are expected in mid-2027, with initial patient proof-of-concept data not due until late 2027 or early 2028. Investors therefore face a long wait before the drug’s effects in people are clear. (Korsana Biosciences)
The proposed safety and brain-delivery advantages remain uncertain: the company’s supporting findings are preclinical, including non-human-primate tests with only three animals per group. The company’s filing warns that preclinical and early clinical results may not predict later trial success. (SEC, SEC)
Korsana has no product revenue and reported a $46.4 million net loss for the third quarter, while saying substantial losses are likely to continue. Its cash runway helps in the near term, but rising development costs could eventually require more capital if trials take longer or the company expands its programmes. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2026.
KRSA Financial Performance
Revenues and expenses
KRSA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.